REITER ||| S:0 E:6 ||| NNP
'S  ||| S:6 E:9 ||| POS
SYNDROME  ||| S:9 E:18 ||| NNP
FOLLOWING  ||| S:18 E:28 ||| NNP
INTRAVASICAL  ||| S:28 E:41 ||| NNP
BCG  ||| S:41 E:45 ||| NNP
THERAPY  ||| S:45 E:53 ||| NNP
FOR  ||| S:53 E:57 ||| IN
UROTHELIAL  ||| S:57 E:68 ||| NNP
CARCINOMA ||| S:68 E:77 ||| NNP
.  ||| S:77 E:79 ||| .
SUMMARY  ||| S:79 E:87 ||| NN
OF  ||| S:87 E:90 ||| IN
CASE  ||| S:90 E:95 ||| NN
REPORTS  ||| S:95 E:103 ||| NNS
OVER  ||| S:103 E:108 ||| IN
THE  ||| S:108 E:112 ||| DT
PAST  ||| S:112 E:117 ||| NNP
13  ||| S:117 E:120 ||| CD
YEARS  ||| S:120 E:126 ||| NNS
IN  ||| S:126 E:129 ||| IN
JAPAN ||| S:129 E:134 ||| NNP
,  ||| S:134 E:136 ||| ,
INCLUDING  ||| S:136 E:146 ||| NNP
OUR  ||| S:146 E:150 ||| NNP
CURRENT  ||| S:150 E:158 ||| NNP
6  ||| S:158 E:160 ||| CD
CASES  ||| S:160 E:166 ||| NNP
Reiter ||| S:166 E:172 ||| NNP
's  ||| S:172 E:175 ||| POS
syndrome  ||| S:175 E:184 ||| NN
is  ||| S:184 E:187 ||| VBZ
one  ||| S:187 E:191 ||| CD
of  ||| S:191 E:194 ||| IN
the  ||| S:194 E:198 ||| DT
rare  ||| S:198 E:203 ||| JJ
complications  ||| S:203 E:217 ||| NNS
following  ||| S:217 E:227 ||| VBG
intravesical  ||| S:227 E:240 ||| JJ
bovis  ||| S:240 E:246 ||| JJ
Bacillus  ||| S:246 E:255 ||| NN
Calmette-Guerin  ||| S:255 E:271 ||| NNS
( ||| S:271 E:272 ||| -LRB-
BCG ||| S:272 E:275 ||| NNP
)  ||| S:275 E:277 ||| -RRB-
treatment ||| S:277 E:286 ||| NN
.  ||| S:286 E:288 ||| .
In  ||| S:288 E:291 ||| IN
this  ||| S:291 E:296 ||| DT
study  ||| S:296 E:302 ||| NN
we  ||| S:302 E:305 ||| PRP
have  ||| S:305 E:310 ||| VBP
reviewed  ||| S:310 E:319 ||| VBN
and  ||| S:319 E:323 ||| CC
discussed  ||| S:323 E:333 ||| VBD
101  ||| S:333 E:337 ||| CD
cases  ||| S:337 E:343 ||| NNS
including  ||| S:343 E:353 ||| VBG
our  ||| S:353 E:357 ||| PRP$
own  ||| S:357 E:361 ||| JJ
6  ||| S:361 E:363 ||| CD
cases  ||| S:363 E:369 ||| NNS
over  ||| S:369 E:374 ||| IN
the  ||| S:374 E:378 ||| DT
past  ||| S:378 E:383 ||| JJ
13  ||| S:383 E:386 ||| CD
years  ||| S:386 E:392 ||| NNS
in  ||| S:392 E:395 ||| IN
Japan  ||| S:395 E:401 ||| NNP
( ||| S:401 E:402 ||| -LRB-
2000-2013 ||| S:402 E:411 ||| NNP
) ||| S:411 E:412 ||| -RRB-
.  ||| S:412 E:414 ||| .
The  ||| S:414 E:418 ||| DT
patients  ||| S:418 E:427 ||| NNS
comprised  ||| S:427 E:437 ||| VBD
70  ||| S:437 E:440 ||| CD
males  ||| S:440 E:446 ||| NNS
and  ||| S:446 E:450 ||| CC
25  ||| S:450 E:453 ||| CD
females  ||| S:453 E:461 ||| NNS
( ||| S:461 E:462 ||| -LRB-
6  ||| S:462 E:464 ||| CD
cases  ||| S:464 E:470 ||| NNS
were  ||| S:470 E:475 ||| VBD
unknown ||| S:475 E:482 ||| JJ
) ||| S:482 E:483 ||| -RRB-
,  ||| S:483 E:485 ||| ,
mean  ||| S:485 E:490 ||| JJ
age  ||| S:490 E:494 ||| NN
of  ||| S:494 E:497 ||| IN
63.1  ||| S:497 E:502 ||| CD
( ||| S:502 E:503 ||| -LRB-
range  ||| S:503 E:509 ||| NN
42  ||| S:509 E:512 ||| CD
-  ||| S:512 E:514 ||| :
91 ||| S:514 E:516 ||| CD
) ||| S:516 E:517 ||| -RRB-
.  ||| S:517 E:519 ||| .
Arthritis  ||| S:519 E:529 ||| NNP
occured  ||| S:529 E:537 ||| VBD
4-5  ||| S:537 E:541 ||| CD
days  ||| S:541 E:546 ||| NNS
after  ||| S:546 E:552 ||| IN
conjunctivitis ||| S:552 E:566 ||| NN
.  ||| S:566 E:568 ||| .
Thirty  ||| S:568 E:575 ||| CD
five  ||| S:575 E:580 ||| CD
( ||| S:580 E:581 ||| -LRB-
55 ||| S:581 E:583 ||| CD
% ||| S:583 E:584 ||| NN
)  ||| S:584 E:586 ||| -RRB-
of  ||| S:586 E:589 ||| IN
68  ||| S:589 E:592 ||| CD
patients  ||| S:592 E:601 ||| NNS
needed  ||| S:601 E:608 ||| VBD
corticosteroid  ||| S:608 E:623 ||| JJ
treatment  ||| S:623 E:633 ||| NN
to  ||| S:633 E:636 ||| TO
control  ||| S:636 E:644 ||| VB
their  ||| S:644 E:650 ||| PRP$
arthritis ||| S:650 E:659 ||| NN
.  ||| S:659 E:661 ||| .
HLA-B27  ||| S:661 E:669 ||| NNP
is  ||| S:669 E:672 ||| VBZ
known  ||| S:672 E:678 ||| VBN
as  ||| S:678 E:681 ||| IN
a  ||| S:681 E:683 ||| DT
risk  ||| S:683 E:688 ||| NN
factor  ||| S:688 E:695 ||| NN
of  ||| S:695 E:698 ||| IN
Reiter ||| S:698 E:704 ||| NNP
's  ||| S:704 E:707 ||| POS
syndrome ||| S:707 E:715 ||| NN
,  ||| S:715 E:717 ||| ,
however ||| S:717 E:724 ||| RB
,  ||| S:724 E:726 ||| ,
positive  ||| S:726 E:735 ||| JJ
rate  ||| S:735 E:740 ||| NN
was  ||| S:740 E:744 ||| VBD
only  ||| S:744 E:749 ||| RB
2.4 ||| S:749 E:752 ||| CD
%  ||| S:752 E:754 ||| NN
( ||| S:754 E:755 ||| -LRB-
n  ||| S:755 E:757 ||| CD
=  ||| S:757 E:759 ||| SYM
41 ||| S:759 E:761 ||| CD
) ||| S:761 E:762 ||| -RRB-
.  ||| S:762 E:764 ||| .
